JPS6259085B2 - - Google Patents
Info
- Publication number
- JPS6259085B2 JPS6259085B2 JP59279113A JP27911384A JPS6259085B2 JP S6259085 B2 JPS6259085 B2 JP S6259085B2 JP 59279113 A JP59279113 A JP 59279113A JP 27911384 A JP27911384 A JP 27911384A JP S6259085 B2 JPS6259085 B2 JP S6259085B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- liver
- placenta
- cosmetics
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000284 extract Substances 0.000 claims description 39
- 210000002826 placenta Anatomy 0.000 claims description 30
- 239000002537 cosmetic Substances 0.000 claims description 24
- 229940040511 liver extract Drugs 0.000 claims description 24
- 241000124008 Mammalia Species 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000003921 oil Substances 0.000 description 11
- 239000008213 purified water Substances 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- -1 flavonol compounds Chemical class 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000002087 whitening effect Effects 0.000 description 5
- 206010040829 Skin discolouration Diseases 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000001557 animal structure Anatomy 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 2
- 239000010696 ester oil Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical class O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- SPAGIJMPHSUYSE-UHFFFAOYSA-N Magnesium peroxide Chemical compound [Mg+2].[O-][O-] SPAGIJMPHSUYSE-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(I) oxide Inorganic materials [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 1
- OMZSGWSJDCOLKM-UHFFFAOYSA-N copper(II) sulfide Chemical compound [S-2].[Cu+2] OMZSGWSJDCOLKM-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- KRFJLUBVMFXRPN-UHFFFAOYSA-N cuprous oxide Chemical compound [O-2].[Cu+].[Cu+] KRFJLUBVMFXRPN-UHFFFAOYSA-N 0.000 description 1
- 229940112669 cuprous oxide Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004995 magnesium peroxide Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229940105296 zinc peroxide Drugs 0.000 description 1
- PLVWNARVBMHCST-UHFFFAOYSA-L zinc;oxidooxy(oxo)borane Chemical compound [Zn+2].[O-]OB=O.[O-]OB=O PLVWNARVBMHCST-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Cosmetics (AREA)
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は動物臓器の抽出液を含有する色白化粧
料に関するものである。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a fair skin cosmetic containing an extract of animal organs.
皮膚上に現われたしみ、そばかすなどの斑点を
除去するため、及び皮膚全体の美白効果をもたら
すため古くから種々の色白化粧料が提供又は研究
開発されている。
BACKGROUND ART Various skin-lightening cosmetics have been provided or researched and developed since ancient times in order to remove spots such as spots and freckles that appear on the skin and to bring about a whitening effect on the entire skin.
古くは過酸化水素、過酸化亜鉛、過酸化マグネ
シウム、過酸化ナトリウム、過ホウ酸亜鉛などの
過酸化物を化粧料中に配合したが、これら過酸化
物はきわめて不安定な物質であるため、保存性あ
るいは化粧料への配合性に難点があり、またその
色白効果も充分であるとはいえなかつた。その後
ビタミンC、システイン、コロイド硫黄などを配
合した化粧料が用いられるようになつたが、なお
十分に満足するものは得られなかつた。 In the past, peroxides such as hydrogen peroxide, zinc peroxide, magnesium peroxide, sodium peroxide, and zinc perborate were incorporated into cosmetics, but since these peroxides are extremely unstable substances, It has problems in storage stability and incorporation into cosmetics, and its skin whitening effect is not sufficient. After that, cosmetics containing vitamin C, cysteine, colloidal sulfur, etc., came into use, but they were still not fully satisfactory.
近時、これらの色白化粧料の美白成分としてコ
ウジ菌などの菌の培養によつて得られるコウジ酸
が皮膚の美白化に効果があり、コウジ酸を用いた
色白化粧料が知られている。例えば、特公昭56−
18569号、特開昭53−3538号公報。また、コウジ
酸の誘導体も研究され、コウジ酸誘導体を含有す
る化粧料も知られている。例えば特開昭56−7710
号、同56−7776号、同56−79616号公報、更にピ
ロン化合物、クロモン化合物、フラボノール化合
物を含有する化粧料も知られている。例えば特開
昭53−3538号、同55−92305号、同55−111410
号、同55−111411号、同55−143908号、同55−
157580号、同57−14517号、同57−35506号、同58
−131911号公報など。 Recently, kojic acid, which is obtained by culturing bacteria such as Aspergillus aspergillus, is effective in whitening the skin as a whitening ingredient in these skin-lightening cosmetics, and skin-whitening cosmetics using kojic acid are known. For example, the
No. 18569, Japanese Patent Application Laid-open No. 53-3538. Further, derivatives of kojic acid have been studied, and cosmetics containing kojic acid derivatives are also known. For example, JP-A-56-7710
Cosmetics containing pyrone compounds, chromone compounds, and flavonol compounds are also known. For example, JP-A-53-3538, JP-A-55-92305, JP-A-55-111410.
No. 55-111411, No. 55-143908, No. 55-
No. 157580, No. 57-14517, No. 57-35506, No. 58
- Publication No. 131911, etc.
また、胎盤抽出液を化粧料に配合した化粧料も
開示されている。例えば特公昭35−15399号公
報。 Cosmetics containing placenta extracts have also been disclosed. For example, Japanese Patent Publication No. 35-15399.
上記開示された各種の色白化粧料において、動
物臓器の抽出液である胎盤抽出液の美白効果を更
に増強する目的で各種動物臓器成分との併用によ
る従来の色白化粧料以上の美白効果を有する化粧
料を提供することを目的とするものである。
Among the various skin-lightening cosmetics disclosed above, cosmetics that have a skin-whitening effect greater than that of conventional skin-lightening cosmetics are created by combining various animal organ components in order to further enhance the skin-whitening effect of placenta extract, which is an extract of animal organs. The purpose of this is to provide a fee.
本発明は胎盤抽出液と動物の肝臓抽出液を含有
することによりきわめてすぐれた色白効果を奏す
る化粧料である。
The present invention is a cosmetic that exhibits an extremely excellent skin-whitening effect by containing a placenta extract and an animal liver extract.
本発明に用いる胎盤抽出液は人又は牛などの動
物の胎盤を洗浄、除血、破砕凍結などの手段を経
て、水溶性部を水により抽出し、更に濾過又は透
析により不純物を除去して得られる水溶液であ
る。 The placenta extract used in the present invention is obtained by washing the placenta of a human or an animal such as a cow, removing blood, crushing and freezing it, extracting the water-soluble part with water, and then removing impurities by filtration or dialysis. It is an aqueous solution.
本発明に使用する胎盤抽出液は、胎盤抽出エキ
スとして一般に市販されて、主に化粧品用原料と
して用いられているものであり、人由来のもの、
牛などの動物由来のものの何れでもよいが、人由
来の胎盤抽出液が好適である。 The placenta extract used in the present invention is generally commercially available as a placenta extract and is mainly used as a raw material for cosmetics, and may be of human origin,
Although any extract derived from animals such as cows may be used, a placenta extract derived from humans is preferred.
本発明に使用する動物の肝臓抽出液は動物の肝
臓を磨砕し抽出したものであり、牛、豚、羊、山
羊などの哺乳動物、鶏などの鳥類の肝臓を水洗除
血した後磨砕して粥状とし、2〜3倍量の水など
の抽出溶媒を加えて、数時間撹拌した後除蛋白操
作を行い、濾過工程を経て、抽出液を得る。この
場合抽出溶媒としては水が好適である。 The animal liver extract used in the present invention is obtained by grinding and extracting the liver of an animal, and is obtained by washing the liver of mammals such as cows, pigs, sheep, and goats, and birds such as chickens with water to remove blood, and then grinding the liver. The mixture is made into a porridge, and 2 to 3 times the amount of an extraction solvent such as water is added thereto. After stirring for several hours, a protein removal operation is performed, and an extract is obtained through a filtration process. In this case, water is suitable as the extraction solvent.
次に本発明に用いる肝臓抽出液の製造例をあげ
る。 Next, an example of producing a liver extract used in the present invention will be given.
製造例 1
豚の肝臓1Kgを磨砕し、2の水を加えて3時
間撹拌抽出を行つたのち、乳酸を加えてPHを4.5
前後に調整し、温度を80℃以上に加熱し、蛋白を
変性せしめて、組織層と一緒に濾別し、濾液は更
に硅藻土を用いて濾過を行い抽出液2.5を得
た。得られた抽出液は比重1.003〜1.008、PH4.5〜
5.5、蒸発残留物2.0g/100ml以下、全窒素90〜
150mg/100ml、ニトロプルシド反応、ジアゾ反応
は共に陽性である。Production example 1 Grind 1 kg of pig liver, add water from Step 2, stir and extract for 3 hours, then add lactic acid to adjust the pH to 4.5.
The temperature was adjusted back and forth, and the temperature was heated to 80°C or higher to denature the protein, which was filtered together with the tissue layer. The filtrate was further filtered using diatomaceous earth to obtain extract 2.5. The obtained extract has a specific gravity of 1.003-1.008 and a pH of 4.5-
5.5, evaporation residue 2.0g/100ml or less, total nitrogen 90~
150mg/100ml, nitroprusside reaction and diazo reaction are both positive.
製造例 2
ニワトリの肝臓10Kgに精製水20を加え、ミキ
サー等で組織をつぶし80〜90℃で3時間撹拌抽出
する。次に10%硫酸でPHを4.5に調整して蛋白
質、組織片を布等で濾過して除去する。更に微小
粒子は遠心分離によるか又はセライト等で濾過し
て抽出液を得る。Production Example 2 Add 20 kg of purified water to 10 kg of chicken liver, crush the tissue with a mixer, etc., and stir and extract at 80 to 90°C for 3 hours. Next, adjust the pH to 4.5 with 10% sulfuric acid, and remove proteins and tissue fragments by filtering with cloth. Furthermore, the microparticles are centrifuged or filtered through Celite or the like to obtain an extract.
次にPHを2.0に調整し50℃前後に加温したもの
に酸化第1銅20gを徐々に加えて2〜3時間ゆる
く撹拌すると、アミノ酸等の銅塩が析出してくる
のでこれを遠心分離して採取する。この銅塩を冷
精製水で数回洗滌し、5の精製水に懸濁された
ものに硫化水素ガスを吹込み、銅を硫化銅として
沈澱させる。濾紙で濾過した液は容量が1/5位に
なるまで減圧濃縮すると過剰の硫化水素が除去で
きる。この抽出液は普通は最終的に20に調整し
て化粧料に使用される。 Next, adjust the pH to 2.0 and warm it to around 50℃, then gradually add 20g of cuprous oxide and stir gently for 2 to 3 hours. Copper salts such as amino acids will precipitate, so centrifuge the mixture. and collect it. This copper salt is washed several times with cold purified water, and hydrogen sulfide gas is blown into the suspension in the purified water in step 5 to precipitate copper as copper sulfide. Excess hydrogen sulfide can be removed by concentrating the liquid filtered through a filter paper under reduced pressure until the volume is reduced to about 1/5. This extract is usually adjusted to a final concentration of 20% and used in cosmetics.
上述の胎盤抽出液と肝臓抽出液を配合する割合
は胎盤抽出液10(重量)に対し、肝臓抽出液5〜
0.01(重量)が好適である。 The proportion of placenta extract and liver extract mentioned above is 10 parts placenta extract (by weight) to 5 parts liver extract.
0.01 (weight) is suitable.
そして、これらの有効成分の化粧料に含有させ
る割合は胎盤抽出液は全化粧料の0.1〜10%(重
量)、肝臓抽出液0.01〜5%(重量)程度で十分
その効果を奏することができる。 The proportion of these active ingredients in cosmetics can be sufficiently effective by containing 0.1 to 10% (by weight) of placenta extract and 0.01 to 5% (by weight) of liver extract. .
本発明の化粧料は主として化粧水、クリーム、
乳液、パツクなどの皮膚化粧料であり、これらの
各化粧料に通常使用される化粧料基剤、助剤など
に胎盤抽出液及び肝臓抽出液を加えて化粧料とす
る。 The cosmetics of the present invention mainly include lotions, creams,
These are skin cosmetics such as milky lotions and packs, and are made by adding placenta extract and liver extract to cosmetic bases, auxiliaries, etc. that are normally used in these cosmetics.
例えば、化粧水においては、精製水にグリセリ
ン、プロピレングリコールなどの保湿剤、皮膚栄
養剤などを溶解し、防腐剤、香料などをアルコー
ルに溶解し、両者を混合して室温下に可溶化する
一般の化粧水の製造において、水溶部に本発明の
有効成分である胎盤抽出液及び肝臓抽出液を加え
て化粧水とする。 For example, in lotions, moisturizers such as glycerin and propylene glycol, skin nutrients, etc. are dissolved in purified water, preservatives, fragrances, etc. are dissolved in alcohol, and the two are mixed and solubilized at room temperature. In the production of a lotion, placenta extract and liver extract, which are the active ingredients of the present invention, are added to the water-soluble part to prepare a lotion.
クリームにおいては、精製水に親水性成分例え
ばグリセリン、ソルビツトなどの保湿剤を添加し
て水相部とし、油相部はミツロウ、パラフイン、
マイクロクリスタリンワツクス、セレシン、高級
脂肪酸、硬化油などの固形油分、ワセリン、ラノ
リン、グリセリドなどの半固形油分、それにスク
ワラン、流動パラフイン、各種エステル油などの
液状油分に防腐剤、界面活性剤などの油性成分を
添加し調製する。このようにして得られた水相部
を加温して、ゆるやかに撹拌しつつ、同温度に加
温された油相部を徐々に添加し乳化してクリーム
とする一般のクリームの製造において、水相部に
本発明の有効成分である胎盤抽出液及び肝臓抽出
液を加えてクリームとする。 In creams, hydrophilic ingredients such as humectants such as glycerin and sorbitol are added to purified water to form the aqueous phase, and the oil phase consists of beeswax, paraffin, etc.
Microcrystalline wax, ceresin, higher fatty acids, solid oils such as hydrogenated oils, semi-solid oils such as vaseline, lanolin, glyceride, liquid oils such as squalane, liquid paraffin, various ester oils, preservatives, surfactants, etc. Prepare by adding oily ingredients. In the production of general cream, the aqueous phase obtained in this way is heated, and while gently stirring, the oil phase heated to the same temperature is gradually added and emulsified to form cream. Placenta extract and liver extract, which are the active ingredients of the present invention, are added to the aqueous phase to form a cream.
乳液においては、精製水にグリセリンなどの保
湿剤、酸又はアルカリのPH調整剤などを加え、加
熱混合してエタノールを加え水相部とし、ミツロ
ウ、パラフインなどの固形油分、ワセリン、ラノ
リンなどの半固形油分、スクワラン、流動パラフ
イン、各種エステル油などの液状油分に、防腐
剤、界面活性剤などの油性成分を添加調整して混
合加熱し油相部とし、油相部を水相部に加えて予
備乳化を行い、これにカルボキシビニルポリマ
ー、カルボキシメチルセルロースなどの保護コロ
イド剤を加え、ホモミキサーで均一に乳化して乳
液とする一般の乳液の製造において、水相部に本
発明の有効成分である胎盤抽出液及び肝臓抽出液
を水相部に加えて乳液とする。 For emulsions, moisturizers such as glycerin, acidic or alkaline PH adjusters, etc. are added to purified water, heated and mixed, ethanol is added to form the aqueous phase, solid oils such as beeswax and paraffin, and semi-containing substances such as vaseline and lanolin are added. Oily components such as preservatives and surfactants are added to liquid oils such as solid oils, squalane, liquid paraffin, and various ester oils, mixed and heated to form an oil phase, and the oil phase is added to the water phase. In the production of general emulsions, in which a protective colloid such as carboxyvinyl polymer or carboxymethyl cellulose is added to the preliminary emulsification and then homogeneously emulsified using a homomixer, the active ingredient of the present invention is added to the aqueous phase. Placenta extract and liver extract are added to the aqueous phase to form a milky lotion.
パツクにおいては、精製水にグリセリンなどの
保湿剤、ポリビニルアルコール、ビーガムなどの
皮膜剤などを加えて膨潤させ、これに必要があれ
ばカオリン、タルク、酸化亜鉛などの粉末を加
え、香料、防腐剤などを溶解したエタノールを加
えてペースト状となるまで混練する一般のパツク
の製造において、本発明の有効成分である胎盤抽
出液及び肝臓抽出液を加えてパツクとする。 In Packaging, moisturizers such as glycerin, film agents such as polyvinyl alcohol, and Veegum are added to purified water to swell it, and if necessary, powders such as kaolin, talc, and zinc oxide are added, and fragrances and preservatives are added. In the production of general packs, in which ethanol in which eg.
次に本発明の実施例をあげる。 Next, examples of the present invention will be given.
例 1
<クリーム>
肝臓抽出液 1.0%
胎盤抽出液 5.0%
ポリオキシエチレンステアリルエーテル 2.09%
ポリオキシエチレンセチルエーテル 2.91%
ミツロウ 4.0%
セタノール 3.0%
イソプロピルパルミテート 2.0%
流動パラフイン 15.0%
ポリエチレングリコールモノステアレート 0.5%
精製水 64.4%
パラオキシ安息香酸メチル 0.1%
例 2
<乳液>
肝臓抽出液 2.0%
胎盤抽出液 4.0%
自己乳化型グリセロールモノステアレート1.11%
ポリオキシエチレンセチルエーテル 1.89%
MCステアリン酸 2.0%
セタノール 1.0%
イソプロピルミリステート 2.0%
精製水 85.90%
パラオキシ安息香酸 0.1%
香 料 微量
例 3
<パツク>
肝臓抽出液 0.6%
胎盤抽出液 6.0%
エタノール 3.0%
パラオキシ安息香酸メチル 0.1%
カルボキシビニルポリマー 1.0%
炭酸カルシウム 0.3%
二酸化チタン 0.02%
精製水 88.98%
香 料 微量
例 4
<化粧水>
肝臓抽出液 3.0%
胎盤抽出液 10.0%
エタノール 10.0%
パラオキシ安息香酸メチル 0.1%
クエン酸 0.2%
香 料 微量
精製水 76.7%
〔発明の効果〕
本発明の有効成分である胎盤抽出液及び肝臓抽
出液の併用による色白効果は各成分の単独による
同効果より相乗的にすぐれたものである。Example 1 <Cream> Liver extract 1.0% Placenta extract 5.0% Polyoxyethylene stearyl ether 2.09% Polyoxyethylene cetyl ether 2.91% Beeswax 4.0% Setanol 3.0% Isopropyl palmitate 2.0% Liquid paraffin 15.0% Polyethylene glycol monostearate 0.5 % Purified water 64.4% Methyl paraoxybenzoate 0.1% Example 2 <Emulsion> Liver extract 2.0% Placenta extract 4.0% Self-emulsifying glycerol monostearate 1.11% Polyoxyethylene cetyl ether 1.89% MC stearic acid 2.0% Setanol 1.0% Isopropyl myristate 2.0% Purified water 85.90% Paraoxybenzoic acid 0.1% Fragrance Trace example 3 <Pack> Liver extract 0.6% Placenta extract 6.0% Ethanol 3.0% Methyl paraoxybenzoate 0.1% Carboxyvinyl polymer 1.0% Calcium carbonate 0.3% Titanium dioxide 0.02% Purified water 88.98% Fragrance Trace amount example 4 <Lotion> Liver extract 3.0% Placenta extract 10.0% Ethanol 10.0% Methyl paraoxybenzoate 0.1% Citric acid 0.2% Fragrance Trace amount purified water 76.7% [Invention Effect] The skin whitening effect obtained by using the placenta extract and liver extract, which are the active ingredients of the present invention, is synergistically superior to the same effect obtained by using each ingredient alone.
以上の効果を下記実験により明らかにする。 The above effects will be clarified through the following experiment.
実験例
試験管にL−ドーパ溶液(10mM)1ml、マツ
クルベイン氏の緩衝液(PH6.8)0.9ml及び試料1
mlを入れ、37℃の恒温水槽で10分間インキユベー
トし、後チロシナーゼ溶液(B16マウスメラノー
マの11000G上清)0.1mlを入れ、よく撹拌した
後、直ちに分光光度計にセツトし、475nmにお
ける吸光度を経時的に測定した。Experimental example: In a test tube, 1 ml of L-dopa solution (10mM), 0.9 ml of Matsukulbane's buffer solution (PH6.8), and sample 1.
After adding 0.1 ml of tyrosinase solution (11000G supernatant of B16 mouse melanoma) and stirring well, immediately set it on a spectrophotometer and measure the absorbance at 475 nm over time. was measured.
試料は、胎盤抽出液、肝臓抽出液、胎盤抽出液
と、これに対し、1/2重量%の肝臓抽出液を含有
する液、及び対照として水である。なお阻止率は
対照を100とした場合、8分後のドーパクロム生
成阻害の割合である。 The samples are placenta extract, liver extract, placenta extract, a liquid containing 1/2% by weight of liver extract, and water as a control. Note that the inhibition rate is the percentage of inhibition of dopachrome production after 8 minutes when the control is set as 100.
以上の測定結果を添付図面で示す。図面より明
らかな如く、肝臓抽出液と胎盤抽出液の併用は、
各単独のものより相乗的にチロシナーゼ活性を阻
害することがわかる。 The above measurement results are shown in the attached drawings. As is clear from the drawing, the combination of liver extract and placenta extract is
It can be seen that tyrosinase activity is inhibited more synergistically than each alone.
なお、本発明の有効成分である肝臓抽出液、胎
盤抽出液はそれぞれ単独でもメラニン生成阻止作
用を有することは知られているが、本発明者の研
究によつて、本実験に使用したB16細胞を使用し
た細胞系でのメラニン生成阻止の機序を解析した
結果、肝臓抽出液はメラニン生成の初期段階に関
与するチロシナーゼの活性に及ぼす銅イオンとキ
レーシヨンしてチロシナーゼ活性を抑制し、メラ
ニンの生成を阻害するのに対し、胎盤抽出液は銅
イオンのキレーシヨンを示さず、胎盤抽出液のメ
ラニン生成抑制の機序は肝臓抽出液のそれと作用
が異なることが実証された。この結果肝臓抽出液
と胎盤抽出液の相異なるメラニン生成阻害作用に
より両者の相乗効果が得られるものと考えられ
る。 Although it is known that the liver extract and placenta extract, which are the active ingredients of the present invention, have the effect of inhibiting melanin production even when used alone, the present inventor's research revealed that the B16 cells used in this experiment As a result of analyzing the mechanism of inhibiting melanin production in a cell system using In contrast, the placenta extract did not show chelation of copper ions, demonstrating that the mechanism of melanin production suppression by the placenta extract is different from that of the liver extract. As a result, it is thought that a synergistic effect of the liver extract and placenta extract can be obtained due to their different melanin production inhibiting effects.
図面は本発明の有効成分のドーパクロム生成を
示す。
The figure shows the dopachrome production of the active ingredient of the invention.
Claims (1)
徴とする色白化粧料。 2 胎盤抽出液が人胎盤抽出液である特許請求の
範囲第1項記載の色白化粧料。 3 肝臓抽出液が哺乳動物、鳥類の肝臓水抽出液
である特許請求の範囲第1項記載の色白化粧料。[Scope of Claims] 1. A fair-skinned cosmetic characterized by containing a placenta extract and a liver extract. 2. A fair-skinned cosmetic according to claim 1, wherein the placenta extract is a human placenta extract. 3. The fair skin cosmetic according to claim 1, wherein the liver extract is an aqueous liver extract of a mammal or bird.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59279113A JPS61155303A (en) | 1984-12-28 | 1984-12-28 | Skin color-lightening cosmetic |
| KR1019850002357A KR920003324B1 (en) | 1984-12-28 | 1985-04-06 | Whitening cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59279113A JPS61155303A (en) | 1984-12-28 | 1984-12-28 | Skin color-lightening cosmetic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61155303A JPS61155303A (en) | 1986-07-15 |
| JPS6259085B2 true JPS6259085B2 (en) | 1987-12-09 |
Family
ID=17606596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59279113A Granted JPS61155303A (en) | 1984-12-28 | 1984-12-28 | Skin color-lightening cosmetic |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS61155303A (en) |
| KR (1) | KR920003324B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3195683B2 (en) * | 1993-03-01 | 2001-08-06 | 丸善製薬株式会社 | Skin cosmetics |
-
1984
- 1984-12-28 JP JP59279113A patent/JPS61155303A/en active Granted
-
1985
- 1985-04-06 KR KR1019850002357A patent/KR920003324B1/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61155303A (en) | 1986-07-15 |
| KR920003324B1 (en) | 1992-04-27 |
| KR860004624A (en) | 1986-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6324967B2 (en) | ||
| EP1226809A1 (en) | Skin texture-improving agents | |
| JP4025600B2 (en) | Topical skin preparation | |
| JPH1160496A (en) | Hyaluronic acid production enhancer | |
| US20030211183A1 (en) | Skin-improving agent | |
| JPS625909A (en) | Preventing agent for skin elastosis | |
| JPS6259085B2 (en) | ||
| JP3044690B2 (en) | Cosmetics | |
| JP5313524B2 (en) | Anti-inflammatory agent and anti-inflammatory skin external preparation | |
| JP5057638B2 (en) | Topical skin preparation | |
| JPH0512324B2 (en) | ||
| JP7813021B2 (en) | Histidase production promoter | |
| JP2610310B2 (en) | External preparation | |
| JPH06321747A (en) | External skin preparation | |
| JPH06321763A (en) | Skin beautifying agent | |
| JP2963136B2 (en) | Cosmetics | |
| JP3354031B2 (en) | External preparation for skin | |
| JP3263246B2 (en) | External preparation for skin | |
| JP2000351722A (en) | Skin cosmetic | |
| JP2003183121A (en) | Skin basement membrane utilization composition | |
| JP3553309B6 (en) | Cosmetics | |
| JP3553309B2 (en) | Cosmetics | |
| JPH0138774B2 (en) | ||
| JPH01121207A (en) | Skin beautifying cosmetic | |
| JPH09151129A (en) | Melamine production-inhibiting agent and preparation for external use for skin |